uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
uniQure N.V. (NASDAQ: QURE) announced six data presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting from May 16-19, 2022, in Washington, D.C. Highlights include an oral presentation on alpha-synuclein lowering in Parkinson's models and several poster sessions covering advancements in AAV gene therapies. Dr. Ricardo Dolmetsch emphasized the innovative potential of the linQURE® cargo platform in silencing mutant C9orf72 in ALS preclinical models. The event underscores uniQure's commitment to advancing gene therapies for severe medical conditions.
Positive
- Presentation of significant data at a leading conference demonstrates research progress.
- Potential advancements in therapies for diseases like ALS and Parkinson's.
- Highlighting the innovative linQURE® cargo platform suggests a competitive edge.
Negative
- None.
Details
News Market Reaction – QURE
The recorded move for QURE in the trading session of this news was +0.95%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including one oral presentation, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Hybrid Congress 2022 Annual Meeting being held May 16-19 in Washington, D.C.
"Our presentations at ASGCT showcase the exceptional work of our uniQure scientists and the breadth of our research pipeline as we advance our investigational AAV gene therapy programs,” stated Ricardo Dolmetsch, Ph.D. president of research and development at uniQure. “We are particularly proud of our studies demonstrating the potential of the linQURE® cargo platform, delivering multiple miRNAs in a single AAV and its application to selectively silence mutant C9orf72 in an ALS preclinical model.”
Specific details on uniQure’s presentations taking place at ASGCT include:
- Title: Alpha-synuclein lowering and rescue of motor phenotype by miRNA-based AAV gene therapy in in vivo Parkinson’s disease models (Abstract #19)
Presenter: Astrid Valles-Sanchez, Ph.D. director of CNS disease biology, uniQure
Oral Session Title: Oligonucleotide Therapeutics
Date and Time: Monday, May 16, 11:15 – 11:30 a.m. EDT
- Title: Construction and optimization of novel adeno-associated virus (AAV) rep gene expression control system for stable rAAV-packaging insect cell line (Abstract #407)
Poster Session Title: Vector Product Engineering, Development or Manufacturing I
Session Date and Time: Monday, May 16, 5:30 – 6:30 p.m. EDT
- Title: Functional transfer of engineered microRNAs through extracellular vesicles: An in vitro proof-of-mechanism study in Huntington’s disease models (Abstract #590)
Poster Session Title: Oligonucleotide Therapeutics II
Session Date and Time: Tuesday, May 17, 5:30 – 6:30 p.m. EDT
- Title: Selective silencing of mutant C9orf72 transcripts (Abstract #552)
Poster Session Title: Gene Targeting and Gene Correction II
Date and Time: Tuesday, May 17, 5:30 – 6:30 p.m. EDT
- Title: AAV5-GLA gene therapy results in sustained long term GLA transgene expression and cross correction of target organs in Fabry disease mouse model (Abstract #1009)
Poster Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases II
Session Date and Time: Wednesday, May 18, 5:30 p.m. EDT
- Title: AAV-mediated APOE gene silencing for Alzheimer’s disease (Abstract #918)
Poster Session Title: AAV Vectors - Preclinical and Proof-of-concept Studies III
Date and Time: Wednesday, May 18, 5:30 p.m. EDT
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other diseases. www.uniQure.com
uniQure Contacts:
| FOR INVESTORS: | FOR MEDIA: | |
| Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 m.cantor@uniQure.com | Chiara Russo Direct: 617-306-9137 Mobile: 617-306-9137 c.russo@uniQure.com | Tom Malone Direct: 339-970-7558 Mobile:339-223-8541 t.malone@uniQure.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.